概念性背景α—干扰素 HBeAg阳性且ALT水平高于正常值上限(以下简称ULN)3倍的患者在完成干扰素治疗后6~12个月后的疗效应答率约30％~40％,对照组仅为10％~20％。在这组患者中,干扰素5MU,每周3次,持续4~6个月的治疗方案对亚洲患者也有效,但其治疗应答率略低于白种患者,这与亚洲患者幼年时感染所致的相对免疫耐受性有关。然而,ALT水平异常的亚洲患者的治疗应答率与白种患者 CONCEPTUAL BACKGROUND: The response rate of patients with HBeAg-positive α-interferon and ALT levels higher than 3 times the upper limit of normal (hereinafter referred to as ULN) is about 30% -40% after 6 to 12 months after completion of interferon treatment. Group only 10% to 20%. In this group of patients, interferon 5MU, 3 times a week for 4 to 6 months of treatment options are also effective in Asian patients, but the response rate was slightly lower than in white patients, which is associated with the Asian Childhood Infection Caused by the relative immune tolerance. However, treatment response rates in Asian patients with abnormal ALT levels were significantly lower in Caucasian patients